PDPN Antibody
Shipped with Ice Packs 
In Stock 
Description
PDPN Antibody Overview
PDPN antibodies bind to specific epitopes on the PDPN glycoprotein, which is upregulated in cancers such as glioma, squamous cell carcinoma, mesothelioma, and melanoma . Key functional domains targeted include:
-
PLAG domains: Critical for PDPN-CLEC-2 interaction, which mediates platelet aggregation and metastasis .
-
Cytoplasmic tail: Associates with ERM proteins to regulate cytoskeletal dynamics and cell motility .
Therapeutic PDPN antibodies primarily aim to disrupt PDPN-CLEC-2 signaling, induce antibody-dependent cellular cytotoxicity (ADCC), or block immunosuppressive pathways in the tumor microenvironment .
Table 1: Key PDPN Antibodies and Their Characteristics
Mechanisms of Action
PDPN antibodies exert antitumor effects through:
-
Neutralization of PDPN-CLEC-2 interaction: Prevents platelet activation, reducing metastasis-promoting factors like TGF-β .
-
ADCC/CDC activation: Humanized antibodies (e.g., humLpMab-23-f) enhance immune effector cell-mediated tumor lysis .
-
Immune checkpoint modulation: PDPN inhibition on T cells reduces exhaustion and boosts antitumor immunity .
Table 2: Efficacy in Preclinical Models
Clinical and Diagnostic Utility
-
Biomarker potential: PDPN overexpression correlates with poor prognosis in lung, breast, and pancreatic cancers .
-
Therapeutic targeting:
Challenges and Limitations
-
Normal tissue expression: PDPN is critical in lung alveoli, lymphatic endothelium, and kidney podocytes, raising toxicity concerns .
-
Epitope variability: Cancer-specific antibodies (e.g., PMab-117) require rigorous validation to avoid off-target effects .
Future Directions
Product Specs
Buffer
PBS with 0.1% Sodium Azide, 50% Glycerol, pH 7.3. Store at -20°C. Avoid freeze/thaw cycles.
Lead Time
Generally, we can ship the products within 1-3 business days after receiving your order. The delivery time may vary depending on the purchase method or location. Please consult your local distributor for specific delivery times.
Synonyms
Aggrus antibody; Glycoprotein 36 KD antibody; Glycoprotein 36 antibody; gp 36 antibody; GP 38 antibody; GP 40 antibody; gp36 antibody; GP38 antibody; GP40 antibody; HT1A 1 antibody; HT1A1 antibody; hT1alpha 1 antibody; hT1alpha 2 antibody; hT1alpha1 antibody; hT1alpha2 antibody; Lung type I cell membrane associated glycoprotein antibody; Lung type I cell membrane associated glycoprotein isoform a antibody; Lung type I cell membrane associated glycoprotein T1A 2 antibody; OTS 8 antibody; OTS8 antibody; OTTHUMP00000009640 antibody; OTTHUMP00000044504 antibody; PA2.26 antibody; PA2.26 antigen antibody; Pdpn antibody; PDPN_HUMAN antibody; Podoplanin antibody; PSEC0003 antibody; PSEC0025 antibody; T1 alpha antibody; T1 ALPHA GENE antibody; T1-alpha antibody; T1A 2 antibody; T1A antibody; TI1A antibody; TIA 2 antibody; TIA2 antibody
Target Names
Uniprot No.
Target Background
Function
Podoplanin (PDPN) mediates effects on cell migration and adhesion through interactions with various partners. During development, it plays a role in separating blood and lymphatic vessels by binding CLEC1B, triggering CLEC1B activation in platelets and leading to platelet activation or aggregation. Conversely, interaction with CD9 attenuates platelet aggregation induced by PDPN. Through MSN or EZR interaction, it promotes epithelial-mesenchymal transition (EMT), leading to ERZ phosphorylation and triggering RHOA activation, resulting in increased cell migration and invasiveness. Interaction with CD44 promotes directional cell migration in epithelial and tumor cells. In lymph nodes (LNs), PDPN controls fibroblastic reticular cells (FRCs) adhesion to the extracellular matrix (ECM) and contraction of the actomyosin by maintaining ERM proteins (EZR; MSN and RDX) and MYL9 activation through association with unknown transmembrane proteins. Engagement of CLEC1B by PDPN promotes FRCs relaxation by blocking lateral membrane interactions, leading to a reduction of ERM proteins (EZR; MSN and RDX) and MYL9 activation. By binding with LGALS8, PDPN may participate in connecting the lymphatic endothelium to the surrounding extracellular matrix. In keratinocytes, PDPN induces changes in cell morphology, exhibiting an elongated shape, numerous membrane protrusions, major reorganization of the actin cytoskeleton, increased motility, and decreased cell adhesion. It controls invadopodia stability and maturation, leading to efficient degradation of the extracellular matrix (ECM) in tumor cells through modulation of RHOC activity, activating ROCK1/ROCK2 and LIMK1/LIMK2 and inactivating CFL1. PDPN is required for normal lung cell proliferation and alveolus formation at birth. It does not function as a water channel or regulate aquaporin-type water channels. Furthermore, it has no effect on folic acid or amino acid transport.
Gene References Into Functions
- Our research suggests that podoplanin expression by cancer-associated fibroblasts could predict poor patient outcome in breast carcinoma. PMID: 30173230
- The mRNA high expression levels of both podoplanin and LYVE-1 genes were statistically significantly associated with a higher rate of LN metastasis (p<0.01) and histological grade (p<0.01 for podoplanin, p<0.05 for LYVE-1). PMID: 30396932
- PDPN participates in the tumorigenesis of odontogenic tumors. PMID: 29577431
- Podoplanin expression serves as a predictive marker of dysplasia in oral leukoplakia. PMID: 29588189
- Lymphatic vessels were identified by the expression of podoplanin. PMID: 29678517
- The study provided evidence that high clonal expansion capacity of podoplanin-positive tumor-initiating cell populations resulted from reduced cell death mediated by podoplanin signaling. PMID: 28059107
- TGF-beta release from platelets is crucial for podoplanin-mediated tumor invasion and metastasis in lung cancer. PMID: 28176852
- This study suggests that podoplanin can be used as a prognostic marker to determine the malignant potential in oral leukoplakias. PMID: 27153448
- High PDPN expression is associated with Inflammatory Rheumatoid Synovial Tissues. PMID: 29377768
- Podoplanin expression in cancer-associated fibroblasts could be an independent predictor of increased risk of recurrence in patients with p-stage IA lung adenocarcinoma. PMID: 28881047
- Studies have found that PDPN is expressed by many types of tumor cells and cancer-associated fibroblasts. Moreover, high levels of PDPN expression are associated with reduced survival and cancer aggression. [review] PMID: 29575529
- Gastric tumor cells revealed no expression of PDPN. However, PDPN was expressed in some cases in spindle-shaped stromal cells within the tumor microenvironment, except for lymphatic vessels. PDPN expression was detected in neither tumor cells nor stromal cells of metastatic regions, such as lymph node and peritoneal metastases. PMID: 29715091
- PDPN contributes to the malignant potential of hepatocellular carcinoma. PMID: 28871005
- In lung adenocarcinoma, the presence of podoplanin-positive cancer-associated fibroblasts (CAFs) was associated with higher numbers of single nucleotide variants (SNVs) in cancer cells. PMID: 29511884
- The prevalence of Oct-3/4 and D2-40-(podoplanin) positive staining of germ cells in testicular biopsies of boys with cryptorchidism were 100% and 50% in age groups less than 6 months; 60% and 17% in 6-12 months; and 12% and 4% in 1-2 years. In all cases, the Oct-3/4 and D2-40 positive germ cells turned negative and the histological pattern normalized completely with age. PMID: 27606906
- The presence of podoplanin expression in peritumoral keratinocytes correlates with aggressive behavior in extramammary Paget's disease (EMPD). PMID: 28381343
- PDPN was induced by hypoxia, and its overexpression undergoes a reduction of adhesion, making it an anti-adhesion molecule in the absence of CCL21, in the tumor. PMID: 28416768
- PDPN acts as an oncogene to promote hypopharyngeal cancer cell viability, migration, and invasion. miR-203 directly targets PDPN to suppress its expression, thus exerting inhibitory effects on cancer metastasis. PMID: 27775879
- Podoplanin expression in cancer-related fibrotic tissues is associated with a poor prognosis, especially in patients with large tumors or lymph node metastases. PMID: 28702871
- Data show that podoplanin (PDPN), CD106 (VCAM-1), and CD248 protein were increased in diseased compared to healthy tendon cells. PMID: 28122639
- Increased expression of twist/podoplanin in ductal breast carcinoma was associated with shorter patient survival. PMID: 28982860
- The study showed that podoplanin increases the motility of fibroblasts and facilitates their interaction with endothelial cells. This, respectively, favors the movement of fibroblasts into the breast tumor stroma and affects tumor angiogenesis, creating a favorable microenvironment for breast cancer progression. PMID: 28938000
- Data suggest that podoplanin (PDPN) might be a pathogenetic determinant of malignant pleural mesothelioma (MPM) dissemination and aggressive growth and may thus be an ideal therapeutic target. PMID: 28182302
- High podoplanin expression in primary brain tumors induces platelet aggregation, correlates with hypercoagulability, and is associated with an increased risk of VTE. PMID: 28073783
- This article provides evidence supporting the implication of podoplanin expression as a marker of poor prognosis of cutaneous squamous cell carcinoma. PMID: 27859466
- A possible crosstalk between epithelial and stromal tumor cells in hepatocellular carcinoma tumor microenvironment may be mediated by podoplanin. PMID: 28348421
- Interestingly, LpMab-17 did not bind to monkey PDPN, whereas the homology is 94% between human PDPN and monkey PDPN, indicating that the epitope of LpMab-17 is unique compared with the other anti-PDPN mAbs. The combination of different epitope-possessing mAbs could be advantageous for PDPN-targeting diagnosis or therapy. PMID: 26937552
- Podoplanin expression is significantly associated with malignant transformation of chronic lip discoid lupus erythematosus into lip squamous cell carcinoma. PMID: 27240861
- The epitope of PMab-21 was identified as Leu44-Glu48, which corresponds to the platelet aggregation-stimulating (PLAG) domain, indicating that Ser61-Ala68 of rabbit PDPN is a more appropriate epitope for immunohistochemistry compared with the PLAG domain. PMab-32 could be useful for uncovering the function of rabbit PDPN. PMID: 26977704
- NZ-1 inhibits the hPDPN-CLEC-2 interaction and is also useful for anti-PA tag MAb. The minimum epitope of LpMab-13 was identified as Ala42-Asp49 of hPDPN using Western blot and flow cytometry. The combination of different epitope-possessing MAbs could be advantageous for hPDPN-targeting diagnosis and therapy. PMID: 27328060
- Low PDPN expression is associated with Uterine Cervical Squamous Intraepithelial Lesions. PMID: 27313335
- High tumoral podoplanin expression could independently predict an adverse clinical outcome for ccRCC patients, and it might be useful in future for clinical decision-making and therapeutic developments. PMID: 27389969
- The present results also suggest that podoplanin+ cells can function as stromal cells for blast cell retention in the AML tumor microenvironment. PMID: 27035421
- We revealed that podoplanin expression in Cancer-associated Fibroblasts was an independent indicator of worse prognosis, irrespective of the expression status of the tumor cells in patients with squamous cell carcinoma of the lung. PMID: 28011493
- High podoplanin expression is associated with lymphatic spread of breast cancer. PMID: 26881521
- High podoplanin expression is associated with lung metastasis. PMID: 26684030
- In esophageal squamous cell carcinoma, high p-mTOR expression was significantly associated with high podoplanin expression and high tumor grade. PMID: 26722465
- These data support a role of podoplanin as an antiapoptotic prosurvival factor in angiotensin II-induced injury of human podocytes. PMID: 26867059
- Podoplanin membrane expression, not only its localization, is a useful prognostic indicator of lung squamous cell carcinoma. PMID: 26700593
- This study uncovers a unique molecular mechanism of lymphangiogenesis in which galectin-8-dependent crosstalk among VEGF-C, podoplanin, and integrin pathways plays a key role. PMID: 27066737
- Expression of Podoplanin in Non-melanoma Skin Cancers and Actinic Keratosis. PMID: 27069135
- Almost all anti-PDPN MAbs recognize a platelet aggregation-inducing (PLAG) domain. PMID: 26492618
- LpMab-12 could serve as a new diagnostic tool for determining whether hPDPN possesses the sialylation on Thr52, a site-specific post-translational modification critical for the hPDPN association with CLEC-2. PMID: 27031228
- Podoplanin may be considered as a predictor marker in assessing malignant transformation of premalignancies and prognosis of oral malignancy. PMID: 25098985
- Data show that the CHO cell line with the stable and high expression of recombinant podoplanin (PDPN)-enhanced green fluorescent protein (EGFP) was constructed successfully, and it could induce platelet aggregation. PMID: 26728373
- PDPN-positive/EpCAM-positive CTC ratio is a prognostic factor, and defining the ratio in patients with HNSCC might be valuable for clinical management. PMID: 24844673
- Podoplanin increased migration of tumor cells and enhanced tube formation activity in endothelial cells independent from VEGF. PMID: 26339454
- Podoplanin overexpression is associated with osteosarcoma. PMID: 26090592
- High podoplanin expression is associated with aggressive tumor behavior, poor prognosis, and metastatic regulation through interaction with VEGF-C. PMID: 26081937
- Podoplanin mediates extracellular matrix degradation by squamous carcinoma cells through control of invadopodia stability. PMID: 25486435
Database Links
Protein Families
Podoplanin family
Subcellular Location
[Podoplanin]: Membrane; Single-pass type I membrane protein. Cell projection, lamellipodium membrane; Single-pass type I membrane protein. Cell projection, filopodium membrane; Single-pass type I membrane protein. Cell projection, microvillus membrane; Single-pass type I membrane protein. Cell projection, ruffle membrane; Single-pass type I membrane protein. Membrane raft. Apical cell membrane. Basolateral cell membrane. Cell projection, invadopodium.; [29kDa cytosolic podoplanin intracellular domain]: Cytoplasm, cytosol.
Tissue Specificity
Highly expressed in placenta, lung, skeletal muscle and brain. Weakly expressed in brain, kidney and liver. In placenta, expressed on the apical plasma membrane of endothelium. In lung, expressed in alveolar epithelium. Up-regulated in colorectal tumors a
Quick Inquiry
Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
